



PharmAust secures core Europe patent

12 September 2017 – Perth, Australia: PharmAust (ASX:PAA), a clinical-stage oncology company, has been issued another core patent in Europe. The patent covers the use of its lead drug monepantel (MPL) as a cancer therapy with protection until 2033.

The patent (No. P021225EP) entitled “Kinase Inhibitors for the Treatment of Cancer”, claims the use aminoacetonitrile derivatives as potent kinase inhibitors for the treatment of cancer.

Aminoacetonitrile derivatives include the Elanco compound, MPL that PharmAust has patented for cancer and is testing in clinical trials.

Dr Richard Hopkins, PharmAust’s CEO commented, “Allowance of this Method of Use patent secures PharmAust’s core intellectual property (IP) in another key world market. It joins the family of patents that have already been granted in important major markets including the US, Australia and China giving the company IP protection. We’re delighted with this outcome as it adds to the breadth and commercial value to our patent portfolio.”

Enquiries:

Dr Richard Hopkins
CEO

Tel: 0405 656 868

rhopkins@pharmaust.com

Dr Roger Aston

Executive Chairman

Tel: 0402 762 204

raston@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a contract synthetic drug manufacturer forecast to generate Aus\$3m in revenues in 2017 at a CAGR of 28%.

PAA’s lead drug candidate is Monopantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.